Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Outlook Therapeutics ( (OTLK) ) is now available.
On February 18, 2026, Outlook Therapeutics received notice from Nasdaq that its common stock had closed below the required $1.00 minimum bid price for 30 consecutive business days, putting it out of compliance with Nasdaq’s continued listing standards. The notification does not immediately affect the stock’s listing, but the company has until August 17, 2026, to lift its closing bid price to at least $1.00 for ten consecutive business days or risk potential delisting, prompting management to monitor the share price and evaluate options such as a reverse stock split and possible appeal procedures if needed.
If Outlook Therapeutics fails to regain compliance by the August deadline and does not qualify for or succeed during an additional 180-day grace period, its stock could be delisted from the Nasdaq Capital Market, which may reduce liquidity and complicate capital-raising efforts. The situation underscores the company’s precarious market positioning and highlights the importance for shareholders of the firm’s forthcoming strategic decisions to address the low share price and maintain its Nasdaq listing.
The most recent analyst rating on (OTLK) stock is a Hold with a $0.41 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.
Spark’s Take on OTLK Stock
According to Spark, TipRanks’ AI Analyst, OTLK is a Neutral.
The score is held down primarily by very weak financial fundamentals (large losses, negative equity, and heavy cash burn) and bearish technicals (price below key moving averages with negative MACD). Valuation provides little support due to a negative P/E and no dividend, while recent FDA setbacks add meaningful regulatory uncertainty.
To see Spark’s full report on OTLK stock, click here.
More about Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company whose common stock is listed on the Nasdaq Capital Market. The company operates within the life sciences sector and is subject to Nasdaq’s continued listing standards, including minimum bid price and market value requirements that affect its access to public equity markets.
Average Trading Volume: 6,136,171
Technical Sentiment Signal: Sell
Current Market Cap: $36.02M
See more insights into OTLK stock on TipRanks’ Stock Analysis page.